S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:RETAReata Pharmaceuticals Stock Price, Forecast & News

$102.21
-2.21 (-2.12 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$99.50
Now: $102.21
$104.59
50-Day Range
$103.31
MA: $152.17
$166.52
52-Week Range
$70.00
Now: $102.21
$257.96
Volume551,640 shs
Average Volume391,392 shs
Market Capitalization$3.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.92
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc. has a strategic collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to develop and commercialize Bard for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.
Read More
Reata Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RETA
CUSIPN/A
Phone972-865-2219

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.52 million
Book Value$7.74 per share

Profitability

Net Income$-290,170,000.00
Net Margins-1,542.06%

Miscellaneous

Employees123
Market Cap$3.40 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$102.21
-2.21 (-2.12 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RETA News and Ratings via Email

Sign-up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

How has Reata Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Reata Pharmaceuticals' stock was trading at $157.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RETA stock has decreased by 35.3% and is now trading at $102.21.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Reata Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Reata Pharmaceuticals
.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Reata Pharmaceuticals
.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals Inc (NASDAQ:RETA) issued its quarterly earnings results on Monday, August, 10th. The company reported ($2.03) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($2.22) by $0.19. The firm earned $3.10 million during the quarter, compared to analyst estimates of $1.46 million. Reata Pharmaceuticals had a negative return on equity of 322.36% and a negative net margin of 1,542.06%. Reata Pharmaceuticals's revenue for the quarter was down 60.3% compared to the same quarter last year.
View Reata Pharmaceuticals' earnings history
.

What price target have analysts set for RETA?

9 equities research analysts have issued 1 year price objectives for Reata Pharmaceuticals' stock. Their forecasts range from $130.00 to $348.00. On average, they expect Reata Pharmaceuticals' stock price to reach $232.22 in the next year. This suggests a possible upside of 127.2% from the stock's current price.
View analysts' price targets for Reata Pharmaceuticals
.

Has Reata Pharmaceuticals been receiving favorable news coverage?

Media headlines about RETA stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Reata Pharmaceuticals earned a news impact score of -1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Reata Pharmaceuticals
.

Who are some of Reata Pharmaceuticals' key competitors?

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), NVIDIA (NVDA), Archrock (AROC) and Inovio Pharmaceuticals (INO).

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the following people:
  • Mr. J. Warren Huff, Chairman, CEO & Pres (Age 65)
  • Dr. Colin J. Meyer, Chief Medical Officer & Exec. VP of Product Devel. (Age 40)
  • Dr. Keith W. Ward, Consultant (Age 49)
  • Mr. Jason D. Wilson, CFO & Exec. VP of Strategy (Age 49)
  • Ms. Elaine Castellanos, VP of Fin. & Accounting

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.63%), FMR LLC (2.61%), Cormorant Asset Management LP (1.20%), TimesSquare Capital Management LLC (1.07%), Goldman Sachs Group Inc. (0.84%) and Deerfield Management Company L.P. Series C (0.79%). Company insiders that own Reata Pharmaceuticals stock include Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward.
View institutional ownership trends for Reata Pharmaceuticals
.

Which institutional investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Precept Management LLC, Emerald Advisers LLC, Corriente Advisors LLC, Emerald Mutual Fund Advisers Trust, Vanguard Group Inc., State of Wisconsin Investment Board, and Bank of America Corp DE. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos, James Warren Huff, and Jason Douglas Wilson.
View insider buying and selling activity for Reata Pharmaceuticals
.

Which institutional investors are buying Reata Pharmaceuticals stock?

RETA stock was acquired by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, FMR LLC, Logos Global Management LP, Goldman Sachs Group Inc., Deerfield Management Company L.P. Series C, MADDEN SECURITIES Corp, Candriam Luxembourg S.C.A., and King Luther Capital Management Corp. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass, and James W Traweek Jr.
View insider buying and selling activity for Reata Pharmaceuticals
.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $102.21.

How big of a company is Reata Pharmaceuticals?

Reata Pharmaceuticals has a market capitalization of $3.40 billion and generates $26.52 million in revenue each year. The company earns $-290,170,000.00 in net income (profit) each year or ($9.54) on an earnings per share basis. Reata Pharmaceuticals employs 123 workers across the globe.

What is Reata Pharmaceuticals' official website?

The official website for Reata Pharmaceuticals is www.reatapharma.com.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company can be reached via phone at 972-865-2219 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.